IGC Pharma Inc Stock Price, News & Analysis

IGC Pharma (NYSE American: IGC) has released its Fiscal Year 2025 financial results and operational highlights, marking significant progress in its Alzheimer's disease research and development programs. The company's lead asset, IGC-AD1, demonstrated positive interim results in its Phase 2 CALMA trial, showing significant reduction in agitation and sleep disturbances in Alzheimer's patients.

Financial results show revenue of $1.2 million in FY2025, slightly down from $1.3 million in FY2024. The company reduced its net loss to $7.1 million ($0.09 per share) from $13 million ($0.22 per share) in FY2024. SG&A expenses decreased by 35% to $4.4 million, while R&D expenses were $3.7 million. The company raised $4.64 million through equity placements and ATM offerings.

Key operational achievements include expanding clinical trial sites across North America, advancing the development of MINT-AD (an AI-based diagnostic tool), and winning two PREPARE Challenge awards. The company plans to complete the CALMA Phase 2 trial, launch a second Phase 2 study for IGC-AD1's disease-modifying effects, and deploy a beta version of MINT-AD in FY2026.

IGC Pharma (NYSE American:IGC) has scheduled a conference call and webcast for Monday, June 30, 2025, at 11:00 a.m. ET to discuss their fiscal year 2025 operational progress and financial results for the period ended March 31, 2025. The financial results will be released before market opening on the same day.

Shareholders and investors can participate via phone by dialing (888) 506 0062 (US) or (973) 528 0011 (International) using access code 370284. A webcast will be available, and a replay can be accessed until July 31, 2025.

IGC Pharma has expanded its Phase 2 CALMA clinical trial for IGC-AD1, a treatment for agitation in Alzheimer's dementia, to a new site at Tekton Research in Yukon, Oklahoma. The expansion, led by board-certified neurologist Dr. David McCoy as principal investigator, aims to diversify the trial population and address regional healthcare disparities in the Oklahoma City metropolitan area. Tekton Research brings extensive experience in conducting clinical trials across various therapeutic areas including Alzheimer's disease, migraine, and vaccines. The site is now accepting patient enrollments, with interested participants able to contact Tekton Research directly through their Yukon facility.

IGC Pharma (NYSE:IGC) has announced a new clinical trial site at Santa Cruz Behavioral (SCB) in Puerto Rico for its CALMA Phase 2 clinical trial, which is investigating IGC-AD1 for agitation in Alzheimer's disease. The strategic location addresses a significant market need, as Puerto Rico has a 12.5% Alzheimer's prevalence rate among those over 65, higher than the 10% rate in non-Hispanic white populations in the U.S.

The selection of Puerto Rico is particularly significant due to its rapidly aging demographic and unique genetic predispositions. Dementia-related medical care in Puerto Rico accounts for over 25% of total societal healthcare costs, exceeding proportions in the continental U.S. This new site complements IGC's existing trial location at the University of Puerto Rico.

IGC Pharma (NYSE American: IGC) presented key genetic toxicology safety data for one of the active pharmaceutical ingredients (APIs) in IGC-AD1, its investigational Alzheimer's disease drug, at the 2025 Genetic Toxicology Association Annual Meeting. The study, conducted by an independent Canadian lab, evaluated melatonin's mutagenic potential using the Bacterial Reverse Mutation Test (Ames test).

The GLP-compliant study tested multiple bacterial strains at concentrations from 1.6 to 5000 µg/plate. Results showed no evidence of mutagenicity at any dose level, with Fold Response values remaining below the mutagenic activity threshold. This safety milestone supports IGC-AD1's development as the company prepares for larger trials and potential commercialization.

IGC Pharma (NYSE American:IGC) announced that its recently appointed advisors have entered into a Share Purchase Agreement on April 21, 2025, to invest approximately $475,000 in the company. The investment price is set at the higher of 30 cents or $0.01 over the last closing price.

Under the agreement, IGC will issue 1,583,333 shares of unregistered common stock, subject to 144 restrictions and a six-month trading lockup period. The private placement completion requires NYSE approval and other customary closing conditions.

The funds will support general corporate purposes and advance IGC's CALMA Phase 2 clinical trial focusing on agitation in Alzheimer's disease. The company views this investment as a vote of confidence from its advisors in IGC's mission to transform Alzheimer's treatment.

IGC Pharma (NYSE American:IGC) has announced the addition of three industry leaders to its Board of Advisors to support its Alzheimer's drug development and AI-driven early dementia detection programs.

The new advisory board members include: Frank Zaccanelli, former President of Dallas Mavericks, who will focus on strategic partnerships and brand ambassador engagement; Robert K. Coughlin, former MassBio CEO and recipient of the 2025 Henri A. Termeer Innovative Leadership Award, who will support regulatory strategy and pharmaceutical relations; and Joseph H. Mangan, a retired brand strategist, who will advise on partnerships with clinical sites, hospitals, and Alzheimer's foundations.

IGC Pharma (NYSE American:IGC) has expanded its Phase 2 CALMA clinical trial by adding Butler Hospital's Memory and Aging Program, affiliated with Brown University's Warren Alpert Medical School. The trial evaluates IGC-AD1, a therapy for agitation in Alzheimer's disease.

Dr. Meghan Riddle, Associate Director of Butler Hospital's Memory and Aging Program and Associate Professor, will lead the trial site. The CALMA study aims to enroll 146 participants across the United States and Canada to assess IGC-AD1's effectiveness in reducing agitation in Alzheimer's patients, a condition affecting most patients and significantly impacting caregivers.

Butler Hospital's Memory and Aging Program is recognized nationally for Alzheimer's research, focusing on prevention, diagnosis, and treatment of neurodegenerative diseases.

IGC Pharma (NYSE American:IGC) has expanded its Phase 2 CALMA clinical trial for IGC-AD1, a treatment targeting agitation in Alzheimer's dementia, by adding the MIND Institute at Miami Jewish Health as a new trial site. The expansion follows promising interim data suggesting potential improvements in patient outcomes.

Miami Jewish Health, with over 85 years of experience in senior healthcare, will contribute to the study under the leadership of Dr. Marc E. Agronin, Chief Medical Officer of MIND Institute and a renowned geriatric psychiatrist. This collaboration aims to accelerate trial completion while reaching a more diverse patient population.